Insilico Medicine, SK Biopharm Sign $2.5B AI Drug Discovery Pact
The heavily backloaded deal targets neurological disorders, with just $18 million paid upfront despite the headline-grabbing potential value.
Insilico Medicine has secured its largest partnership with an Asia-Pacific company to date, signing a deal with SK Biopharmaceuticals worth up to $2.5 billion to discover drugs for neurological conditions using artificial intelligence.
The agreement, announced June 22, adopts an increasingly common structure in AI drug discovery: a massive headline figure supported by minimal upfront commitment. SK Biopharm will pay just $18 million in upfront and near-term milestone payments, with the remainder contingent on successful development and commercialization.
How the collaboration works
Under the partnership, Insilico will deploy its Pharma.AI platform to design and optimize drug candidates targeting neuroinflammatory, neurodegenerative, and rare neurological disorders affecting the central nervous system. The specific diseases have not been disclosed.
SK Biopharm will handle late-stage clinical development and commercialization, leveraging infrastructure built around Xcopri (cenobamate), its epilepsy therapy. The Korean company views the arrangement as a "scalable and repeatable growth platform" for future target discovery beyond its current epilepsy focus, according to president and CEO Donghoon Lee.
Alex Zhavoronkov, co-CEO and chief business officer at Insilico, said the collaboration aims to produce therapies spanning "both traditional small molecules and advanced new modalities."
Why it matters
The deal structure reflects a broader pattern in AI-pharma partnerships: pharmaceutical companies are willing to attach billion-dollar valuations to AI collaborations while minimizing financial risk through performance-based payments. This approach allows established drugmakers to access AI capabilities without major capital commitments, while AI companies secure validation and potential future revenue. For Insilico, the partnership extends a dealmaking surge following its Hong Kong IPO in late 2025, demonstrating sustained industry interest in AI-driven drug discovery despite questions about when these platforms will deliver approved therapies.
Part of a broader dealmaking streak
The SK Biopharm agreement continues a busy period for Insilico following its Hong Kong initial public offering at the end of 2025. In January, the company partnered with Fosun Pharma's Hygtia Therapeutics on a brain-penetrant NLRP3 inhibitor for Parkinson's disease. In March, it expanded an existing deal with China's Tenacia Biotechnology to include an additional asset for neurological diseases.
Beyond the central nervous system, Insilico signed a deal with Eli Lilly in March worth up to $2.75 billion, with $115 million paid upfront for exclusive licenses to certain preclinical oral therapeutics. The company has also inked partnerships with Servier (up to $888 million, focused on cancer) and Qilu Pharmaceutical (up to $120 million, targeting cardiometabolic diseases).
For SK Biopharmaceuticals, the Insilico collaboration aligns with a broader push into digital health and AI technologies under the slogan "SK, AI for Every Patient." In October 2025, the company launched Mentis Care, an AI-driven digital health joint venture with Eurofarma to commercialize an epilepsy management platform combining real-time seizure detection and clinical decision support tools.
The details were first reported by Fierce Biotech.
This is an original analysis by the Omega editorial team. Source reporting: AI Watch.
Want systems like this working for your business?
Book a Call
